comparemela.com

Latest Breaking News On - American society of clinical oncology annual meeting - Page 3 : comparemela.com

Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib

CAMBRIDGE, Mass., June 01, 2024 Cullinan Therapeutics, Inc. , a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced positive initial data in.

United statesUnited kingdomRose weldonJeffrey jonesJeff jonesAlexander spiraGlobenewswire incAmerican society of clinical oncology annual meetingVirginia cancer specialists research instituteTaiho pharmaceutical co ltdTaiho oncology incCullinan pearl corpExchange commissionCullinan therapeutics incGreater china to zai labChief medical officer

Adcetris Regimen Outperforms Intense Chemo in Classical Hodgkin Lymphoma

An Adcetris-based treatment regimen improved progression-free survival and was more tolerable for patients with classical Hodgkin lymphoma.

United statesPeter borchmannUniversity hospital cologneAmerican society of clinical oncology annual meetingClinical oncology annualIntegrated oncology

Rybrevant Plus Leclaza May Be New Standard for EGFR-Mutant Lung Cancer

Rybrevant plus Leclaza outperformed Tagrisso regarding progression-free survival in patients with EGFR-mutant non-small cell lung cancer.

Comunidad autonoma de catalunaUnited statesRybrevant leclazaEnriqueta felipAmerican society of clinical oncology annual meetingClinical oncology annual meetingNeck cancer unitHebron hospital

Rybrevant Plus Leclaza Has Very Potent Activity in Lung Cancer Subset

Rybrevant plus Leclaza had promising response and progression-free survival rates in patients with EGFR-mutant non-small cell lung cancer.

South koreaUnited statesByoung chul choYonsei cancer centerAmerican society of clinical oncology annual meetingClinical oncology annual

FutureBridge set to engage with industry leaders at 2024 ASCO® Annual Meeting and BIO 2024 International Conference

UTRECHT, Netherlands, May 30, 2024 /PRNewswire/ FutureBridge, a leading techno-commercial consulting and advisory company focussing on R&D, innovation, strategy, scientific evidence, markets

United statesSan diegoPrnewswire futurebridgeManoj jiandaniShivali jasrotiaInternational conferenceAmerican society of clinical oncology annual meetingBristol myers squibbGilead sciencesAmerican societyClinical oncologyAnnual meetingSenior consultantBristol myersEarly signalsPractice area head

vimarsana © 2020. All Rights Reserved.